Response Genetics Performing MAGE-A3 Screens for Late-Stage GSK Lung Cancer Rx

Response Genetics claims that its collaboration with GSK to screen patients for MAGE-A3 for an investigational antigen-specific immunotherapeutic stands to be the “largest clinical trial ever conducted in lung cancer treatment.”

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.